References
- Labelle M Belley M Gareau Y Discovery of MK-0476, a potent and orally active leukotriene D4 receptor antagonist devoid of peroxisomal enzyme induction Bioorg Med Chem Lett 1995 5 3 283 288
- De Lepeleire I Reiss TF Rochette F Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma Clin Pharmacol Ther 1997 61 1 83 92 9024176
- Blake KV Montelukast: data from clinical trials in the management of asthma Ann Pharmacother 1999 33 12 1299 1314 10630831
- Sorkness CA Reiss TF Zhang J Bronchodilation with a selective and potent leukotriene D4 (LTD4) antagonist (MK-0476) in patients with asthma Am J Respir Crit Care Med 1994 149 A216
- Reiss TF Altman LC Chervinsky P Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma J Allergy Clin Immunol 1996 98 3 528 534 8828530
- Cheng H Leff JA Amin R Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females Pharm Res 1996 13 3 445 448 8692739
- Balani SK Xu X Pratha V Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile Drug Metab Dispos 1997 25 11 1282 1287 9351905
- Al Omari MM Zoubi RM Hasan EI Khader TZ Badwan AA Effect of light and heat on the stability of montelukast in solution and in its solid state J Pharm Biomed Anal 2007 45 3 465 471 17719198
- International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Stability Testing of New Drug Substances and Products: Q1A(R2) ICH Harmonised Tripartite Guideline. Current Step 4 version. Geneva ICH 2003 Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2_Guideline.pdf. Accessed December 17, 2012.
- Colorcon. Opadry® fx™ special effects film coating system [web page on the Internet]. West Point, PA and Dartford: Coloron; nd. Available from: http://www.colorcon.com/products/coatings/immediate-release/opadry-fx. Accessed December 17, 2012.
- Gulian S Friend B Taste Masking Performance and Stability of Opadry®tm, a Taste Mask Film Coating System West Point, PA and Dartford Colorcon 2004 Available from: http://www.colorcon.com/literature/marketing/fc/Opadry%20tm/poster_tastemask_opadrytm.pdf. Accessed February 19, 2012.
- US Pharmacopeial Convention United States Pharmacopeia 30th edition Rockville, MD US Pharmacopeial Convention 2007 1923 1927
- US Food and Drug Administration (FDA) Dissolution methods [webpage on the Internet] Silver Spring, MD FDA nd. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm?PrintAll=1. Accessed December 17, 2012.
- Shargel L Wu-Pong S Yu AB Applied Biopharmaceutics and Pharmacokinetics 5th ed New York, NY McGraw-Hill 2005 123 131
- Shah VP Medha KK Dighe SV Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report Eur J Drug Metab Pharmacokinet 1991 16 4 249 255 1823867
- Wheatley TA Water soluble cellulose acetate: a versatile polymer for film coating Drug Dev Ind Pharm 2007 33 3 281 290 17454061
- Merck Sharp and Dohme Ltd Singulair 10 mg tablets [summary of product characteristics]. eMC; updated February 7, 2012. Available from: http://www.medicines.org.uk/emc/medicine/17718/SPC. Accessed December 17, 2012.
- Sauer D Zheng W Coots LB McGinity JW Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55 Eur J Pharm Biopharm 2007 67 2 464 475 17451929
- Parikh NH Porter SC Rohera BD Aqueous ethylcellulose dispersion of ethylcellulose. I. Evaluation of coating process variables Pharm Res 1993 10 4 525 534 8483834
- Krogars K Heinämäki J Vesalahti J Marvola M Antikainen O Yliruusi J Extrusion-spheronization of pH-sensitive polymeric matrix pellets for possible colonic drug delivery Int J Pharm 2000 199 2 187 194 10802412
- Rege PR Garmise RJ Block LH Spray-dried chitinosans. Part II: in vitro drug release from tablets made from spray-dried chitinosans Int J Pharm 2003 252 1–2 53 59 12550780
- Frisbee SE Mehta KA Mcginity JW Processing factors that influence the in vitro and in vivo performance of film-coated drug delivery systems Drug Deliv. 2002 2 72 76
- FDA Guidance for Industry: Statistical Approaches to Establishing Bioequivalence Silver Spring, MD FDA 2001 Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070244.pdf. Accessed December 17, 2012.
- European Medicines Agency (EMEA) Committee for Proprietary Medicinal Products Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98. London EMEA 2001 Available from: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003519. Accessed December 17, 2012.